YITU Attended ICCV 2019 with Self-developed Cloud AI Chip, Showcasing Integrated Software and Hardware Strength
1.11.2019 13:00:00 EET | Business Wire | Press release
The 17th International Conference on Computer Vision (ICCV 2019) was convened in Seoul, South Korea this week. YITU Technology attended the conference with its latest researches. Known as the world’s top-notch computer vision conference, ICCV is held once every two years, of which the papers and topics manifest the highest research level and technical growth trend in the field of computer vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191101005240/en/
YITU AI chip QuestCore TM (Photo: Business Wire)
As a globally leading artificial intelligence company, YITU has been always standing at the frontier of AI innovations. From October 29th to November 1st, AI researchers from YITU present their up-to-date research findings and industrial practices at the ICCV 2019, including QuestCoreTM, a cloud AI chip developed by YITU, so as to communicate with and learn from a wider range of research communities.
“The peak of artificial intelligence algorithm performance has shifted from academia to industry,” said Dr. Yan Shuicheng, CTO of YITU, “Academia and industry need in-depth cooperation, to better boost increasing peak performance of the entire AI ecological algorithm.”
As a world-known scholar in computer vision and machine learning, Dr. Yan joined YITU in August this year, the company's strong R&D and engineering strength is one of the important reasons for him to join. Dr. Yan, as an IEEE Fellow, IAPR Fellow and ACM Distinguished Scientist, has published more than 600 papers in top international journals and conferences, with more than 40,000 citations, H-index 98.
YITU released its self-developed cloud AI chip QuestCoreTM in May, 2019. Integrated with its world-class AI algorithm and advanced chip design philosophy, it is so far the most intelligent and cost-effective video analysis chip in the world. This chip indicates a successful practice of YITU to follow the strong coupling trend between AI algorithms and chip design. Relevant achievements are also exhibited on ICCV 2019.
According to data from Tsinghua University, computer vision applications accounted for nearly 35% of the total artificial intelligence applications in 2019, and have become an important support for the development of various industries.
YITU is building the Visual Computing National New Generation Artificial Intelligence Open Innovation Platforman, a national AI infrastructure, to align with the developers of algorithm, chip and product, and provide full chain optimization services covering algorithm, chip and entire tool chain.
“We will help to enhance the overall performance of visual computing smart industry solution,” said Dr. Yan Shuicheng. “Help to integrate development experience and domain knowledge, and promote industrial innovation and cooperation."
About YITU
YITU Technology is one of the few startups in the world that has pioneered many cutting-edge technologies in many critical Artificial Intelligent (AI) fields such as computer vision, speech recognition, natural language processing, intelligent decision-making and AI chips.
YITU Technology is dedicated to advancing breakthrough technologies in AI. Powered by world-class AI algorithms, YITU's self-developed AI chip QuestCore™ can be applied to a variety of scenarios to provide cost-effective and market-competitive solutions. YITU is the only company worldwide to be awarded championship in facial recognition vendor test three times by National Institute of Standards and Technology (NIST), as well as first place in the test hosted by the Intelligence Advanced Research Projects Activity (IARPA). YITU’s self-developed speech recognition technology has been tested to be best-in-class for the Mandarin language. Nature Medicine, a leading academic journal, published on YITU’s latest breakthrough in intelligent pediatric diagnostic technology based on NLP this February, which has been so far the highest-level paper in the field of artificial intelligence research in China.
Leveraging AI technology, YITU is empowering diverse industries. It provides world-leading innovative technologies and products in several sectors including Intelligent City, Smart Finance, Intelligent Healthcare, Smart Retail, AI Chips and AI Pharmaceuticals. YITU is so far the only AI company nationwide able to provide intelligent management technology in mega-cities and complex conditions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191101005240/en/
Contact information
Yitu Tech
Contact name: Alice Deng
Tel:021 - 52559588
Email:media@yitu-inc.com
Website: https://www.yitutech.com/en
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom